{"disease":{"id":"maintenance-therapy-of-unresectable-urothelial-carcinoma-in-patients-who-have-received-chemotherapy","name":"Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"avelumab","indication_name":"Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bavencio","generic_name":"avelumab","company_name":"Merck KGaA","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":69,"revenue":"400","mechanism":"Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"bavencio","indication_name":"Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bavencio","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}